Join our webinar for insights on the journey from preclinical to clinical studies in pulmonary arterial hypertension (PAH), and much more.

Overview

This webinar represents a collective effort to propel the knowledge exchange within our community. It offers a unique opportunity to deepen your understanding, engage in critical discussions, and foster collaborations in this rapidly evolving field.

Objective

Distinguished experts from University Hospital of Antwerp and SGS, unravel the latest advancements from preclinical to clinical studies in pulmonary arterial hypertension (PAH). They will give profound insights into current treatments, late-phase Investigational Medicinal Products (IMPs) and early-stage innovations tailored for this indication.

Agenda

Current standard of care for PAH treatment
Innovations in late-phase IMPs and vaccinations
Preclinical and early phase developments in this field
Q&A session: engage with experts, clarify your concerns

Speakers

Jelle

Klein

Medical Director CPU, SGS

Steven

Haine

Antwerp University Hospital and University of Antwerp

Target Audience: The webinar is aimed at all pharmaceutical and biotech professionals, as well as esteemed pulmonologists, general practitioners, cardiologists and clinicians.

Language: English

Can't make a live session? Register now and receive a complimentary recording after the live event.